Home > News > COPD indication for Foster pMDI

Autorizzo al trattamento dei miei dati personali
ai sensi del D.L. 30 giugno 2003 n. 196
Edit email address
Invalid email
Your request has been sent successfully
Authorize the processing of personal data

COPD indication for Foster pMDI

Date: 21/03/2014

Foster is a fixed combination of beclomethasone dipropionate (corticosteroid) and formoterol fumarate (a long-acting β2-agonist with rapid onset of effect) to be taken by inhalation. In 2006 the drug was approved for the maintenance therapy of asthma; after its first launch in Germany on October 2006, it is now sold in over 35 countries worldwide, including Russia and China. Further launches are planned throughout 2014.

Foster is also available as a DPI ( Dry Powder Inhaler, in NEXThaler device) in the asthma indication. Foster’s key feature is its extra-fine formulation, which guarantees the uniform distribution and high drug deposition throughout the entire bronchial tree, including the small airways. In 2013, Foster pMDI obtained the approval of the MART (Maintenance And Reliever Therapy) posology and the approval of COPD indication is another important achievement for this product. With the new approval in COPD, Foster pMDI is achieving a broader therapeutic indication in patients with obstructive respiratory disorders and it is expected to become one of the recommended inhalation options in this steadily increasing population of patients.

About Chiesi Farmaceutici S.p.A

Chiesi Farmaceutici is a research-focused international group, with more than 75 years of experience headquartered in Parma (Italy). Chiesi researches, develops and commercializes innovative pharmaceutical solutions in the respiratory therapeutics and specialist medicine areas. In 2013, Chiesi achieved sales of over 1.2 billion Euros, constituting double digit growth over 2012. Its R&D centers in Parma (Italy), Paris (France), Rockville (USA), Chippenham (UK) and the R&D team of the newly-acquired Danish company Zymenex, integrate their efforts to advance Chiesi's pre-clinical, clinical and registration programs. The Chiesi Group employs approximately 3900 people, 480 of which are dedicated to R&D activities. For more information, please visit www.chiesi.com.